Advertisement
Screener

4D Molecular Therapeutics, Inc. (FDMT) Analyst Insights

RatingsBuyHoldSellOther ratingsLast CloseAverage TargetUpsideHigh TargetLow Target
(m)(m)(m)(m)(m)$12.23(m)(m)(m)(m)
Past 12 Months12 Month ForecastLast Close$12.23High(m)Average(m)Low(m)2025-11-062026-11-06
DateStockAnalystFirmPrice When RatedPrice TargetUpside / DownsideRatingPerformance
2026-09-11FDMT
4D Molecular Therapeutics, Inc.
Eliana Merle, CFABarclays$13.49$28.00+107.56%Overweight
2025-11-10FDMT
4D Molecular Therapeutics, Inc.
Eliana Merle, CFABarclays$10.50$33.00+214.29%Overweight
2025-05-08FDMT
4D Molecular Therapeutics, Inc.
Eliana Merle, CFABarclays$3.24$38.00+1,072.84%Overweight
2024-04-15FDMT
4D Molecular Therapeutics, Inc.
Eliana Merle, CFABarclays$26.35$45.00+70.78%Overweight

Similar stocks

Stock NameCountryMarket CapPE Ratio
Solid Biosciences Inc. (SLDB)United States$0.802B-5.07
Aura Biosciences, Inc. (AURA)United States$0.639B-5.61
Attovia Therapeutics, Inc. (ATTO)United States$0.828B
Candel Therapeutics, Inc. (CADL)United States$0.885B-8.86
Sana Biotechnology, Inc. (SANA)United States$0.886B-4.92
Allogene Therapeutics, Inc. (ALLO)United States$0.574B-4.33
Prime Medicine, Inc. (PRME)United States$0.557B-3.54
Autolus Therapeutics plc (AUTL)$0.506B-1.52
Odyssey Therapeutics, Inc. (ODTX)United States$0.960B
Entera Bio Ltd. (ENTX)$0.485B